Hsbc Holdings PLC Invests $3.30 Million in Repligen Corporation $RGEN

Key Points

• HSBC Holdings acquired 24,170 Repligen shares during the second quarter, valued at approximately $3.30 million. Institutional investors and hedge funds collectively own 97.64% of the company.
• Analysts remain broadly bullish, with an average “Buy” rating and a consensus price target of $166.43; targets range from $160 to $185.
• Repligen exceeded quarterly expectations, reporting adjusted EPS of $0.54 versus the $0.45 consensus and revenue of $204.13 million, up 11.9% year over year. Shares opened at $176.27, near the company’s 52-week high of $188.73, but trade at a lofty P/E ratio of 241.47.

Hsbc Holdings PLC acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 24,170 shares of the biotechnology company's stock, valued at approximately $3,302,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the 3rd quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $36,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Repligen during the second quarter worth $52,000. Farther Finance Advisors LLC grew its position in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 128 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 104 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on RGEN. Evercore restated an "outperform" rating and issued a $160.00 price objective on shares of Repligen in a report on Monday, July 6th. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Royal Bank Of Canada started coverage on Repligen in a research report on Thursday, May 14th. They set an "outperform" rating and a $160.00 target price on the stock. Barclays raised their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company increased their target price on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $166.43.

Repligen Price Performance

RGEN opened at $176.27 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market cap of $9.95 billion, a P/E ratio of 241.47, a PEG ratio of 3.22 and a beta of 1.03. The firm has a 50-day moving average of $151.99 and a 200 day moving average of $133.09. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.Repligen's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, research analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.60% of the stock is owned by insiders.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source